NCT06131918View on ClinicalTrials.gov

Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

May 5, 2024

Conditions
Peripheral Diabetic Neuropathy
Interventions
DRUG

Resveratrol, Alpha lipoic acid, Super oxide dismutase

Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD

DRUG

Resveratrol

Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD

DRUG

Alpha lipoic acid

Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD

DRUG

Super Oxide Dismutase

Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD

Trial Locations (1)

Unknown

Syed Hamid Habib, Peshawar

All Listed Sponsors
lead

Khyber Medical University Peshawar

OTHER